| Donald Boone, DC | |
|
144 Stony Point Road, Santa Rosa, CA 95401 | |
| (707) 521-4500 | |
| (707) 544-4626 |
| Full Name | Donald Boone |
|---|---|
| Gender | Male |
| Speciality | Physician Assistant |
| Location | 144 Stony Point Road, Santa Rosa, California |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1124137732 | NPI | - | NPPES |
| DC18337 | Other | CA | OTHER |
| PA15393 | Other | CA | OTHER |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 111N00000X | Chiropractor | DC18337 (California) | Primary |
| 363A00000X | Physician Assistant | PA15393 (California) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Donald Boone, DC 144 Stony Point Road, Santa Rosa, CA 95401 Ph: (707) 521-4500 | Donald Boone, DC 144 Stony Point Road, Santa Rosa, CA 95401 Ph: (707) 521-4500 |
News Archive
"The big three" infections AIDS, TB and malaria have caught the world's attention but other disabling and fatal infectious diseases in Africa are being ignored, say three eminent tropical disease researchers in the international health journal PLoS Medicine.
NPR explores the reasons for the high rates of HIV/AIDS infection among black women: "African-Americans, who only make up 1+2 percent of the U.S. population, account for nearly half of those living with HIV. More specifically, black women represent 61 percent of the new HIV cases among all women.
A foundational study published in top biomedical journal PNAS (Proceedings of the National Academy of Sciences) this week by researchers at the University of Toronto's Institute of Biomaterials & Biomedical Engineering and the McEwen Centre for Regenerative Medicine have identified the optimal structure and cell ratio associated with heart function - and the discovery has already led the team to another research first: the engineering of the first-ever living, three-dimensional human arrhythmic tissue.
A Nature Biotechnology article published online January 17 reveals that Xencor Inc.'s proprietary Fc engineering extends the half-life of antibodies while maintaining their potency and extending duration of action. These results, published in an article entitled, "Enhanced antibody half-life improves in vivo activity" demonstrate the potential of Fc engineering to impact the flexibility of route, schedule and dose for nearly any antibody.
According to a new study an older antipsychotic drug has been found to be both cheaper and as effective for some patients with schizophrenia as the newer drugs on the market.
› Verified 1 days ago